Biosimilar drugs step up complexity


The first ever generic monoclonal antibody therapies have been recommended for approval in Europe. The two biosimilar versions of infliximab (Johnson & Johnson’s Remicade) have passed assessment by the European Medicines Agency’s committee for medicinal products for human use, but will need to be fully approved by the European commission before they can be marketed.

Monoclonal antibodies are significantly larger and more complex than previously approved biosimilars, which include growth hormones and erythropoietin. Proving that they are functionally similar to the original drug is therefore complex. Both manufacturers, Celltrion and Hospira, had to complete human trials to prove that their generic infliximab products were as safe and effective as Remicade in treating autoimmune diseases.

Johnson & Johnson still has patent protection for Remicade in the majority of European countries. This means that the biosimilars, if finally approved, will either have to launch first in peripheral markets, or try to overturn the patent in court.


Related Content

Cast from the same mould?

31 May 2011 Premium contentFeature

news image

Development of generic biological drugs is gathering momentum. But as Rajendrani Mukhopadhyay finds out, the welcome they are...

First biosimilar antibody drugs approved in Europe

11 September 2013 Business

news image

European commission gives final approval to generic infliximab copies

Most Read

UC Davis chemist sentenced to four years over explosion

19 November 2014 News and Analysis

news image

Postdoc sentenced over attempt to make explosive device and reckless disposal of hazardous waste

Spanish fly

10 October 2013 Podcast | Compounds

news image

Helen Scales looks at cantharidin, the active ingredient in this famous aphrodisiac

Most Commented

Beetle behind breath test for bank notes

17 November 2014 Research

news image

Photonic crystal inks inspired by longhorn beetle could help to fight counterfeiting

Toxicologists enter the fray on endocrine disruptors

29 July 2013 News and Analysis

news image

Open letter urges the European commission to consult with the scientific community before enacting any regulation